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Abstract. Classical Hodgkin lymphoma (cHL) is a relatively rare disease, with approximately 
9,200 estimated new cases and 1,200 estimated deaths per year in the United States. First-line 
chemo-radiotherapy leads to cure rates approaching 80% in patients with advanced-stage 
disease. However, 25 to 30% of these patients are not cured with chemotherapy alone (i.e., the 
ABVD regimen) and show either primary refractoriness to chemotherapy, early disease relapse or 
late disease relapse. Second-line salvage high-dose chemotherapy (HDC) and autologous stem cell 
transplantation (SCT) have an established role in the management of refractory/relapsed cHL, 
leading to durable responses in approximately 50% of relapsed patients and a minority of 
refractory patients. However, due to the poor responses to second-line salvage chemotherapy 
and dismal long-term disease control of primary refractory and early relapsed patients, their 
treatment represents an unmet medical need. Allogeneic SCT represents, by far, the only 
strategy with a curative potential for these patients; however, as discussed in this review, it’s role 
in cHL remains controversial. Despite a general consensus that early relapsed and primary 
refractory patients represent a clinical challenge requiring effective treatments to achieve long-
term disease control, there has been no consensus on the optimal therapy that should be offered 
to these patients. This review will briefly discuss the clinical results and the main issues 
regarding autologous SCT as well as the current role of allogeneic SCT. 
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Introduction. Classical Hodgkin lymphoma (cHL) is a 
relatively rare disease, with approximately 9,200 
estimated new cases and 1,200 estimated deaths per 
year in the United States.1 First-line chemo-
radiotherapy yields cure rates approaching 80% in 
patients with advanced-stage disease.2,3 However, 25 to 
30% of these patients are not cured with modern 
chemo-radiotherapy and show either primary 
refractoriness to chemotherapy, as defined by disease 
progression during or within 3 months of doxorubicin-
based chemotherapy, early disease relapse (i.e., within 
12 months after the end of first-line treatment) or late 
disease relapse.4 Second-line salvage high-dose 
chemotherapy (HDC) and autologous stem cell 
transplantation (SCT) have become the standard of care 
for refractory/relapsed cHL, leading to durable 
responses in approximately 50% of relapsed patients 
and a minority of refractory patients.5-12 However, due 
to the poor responses to second-line salvage 
chemotherapy and dismal long-term disease control of 
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primary refractory and early-relapsed patients, their 
treatment represents an unmet medical need. Despite a 
general consensus that these patients represent a 
clinical challenge requiring effective treatments, there 
remains no consensus on the optimal therapy to be 
offered to early relapsed and primary refractory 
patients.13,14 Disease recurrence or progression after 
autologous SCT is associated with a very poor 
prognosis and the median survival time from 
transplantation failure ranges from 12 to 29 months in 
different series.15-18 Various therapeutic options are 
currently available for relapsed/refractory cHL patients 
who fail autologous SCT.19 Among these, brentuximab 
vedotin (BV), nivolumab and bendamustine have 
demonstrated extraordinary efficacy.20-24 However, 
both drugs are limited in terms of long-term disease 
control, and by far, allogeneic SCT represents the only 
strategy with a curative potential for multirelapsed and 
refractory patients.25-27 Nevertheless, among patients 
who receive allogeneic SCT, long-term progression-
free survival (PFS) does not exceed 25% to 35% in 
most series, and disease relapse is associated with an 
exceedingly poor outcome, with less than half of 
patients surviving for 3 years.25,26,28-31 This review will 
briefly discuss the clinical results and the main issues 
regarding autologous SCT and the current role of 
allogeneic SCT. 
 
Autologous SCT.  
According to retrospective and prospective, as well as 
randomized studies, HDC followed by autologous SCT 
can rescue 30 to 80% of relapsed/refractory cHL 
patients. On average, 50% of patients who receive 
autologous SCT relapse or progress within 12 months 
after transplant. Randomized studies (Table 1) have 
failed to report significantly improved overall survival 
(OS), likely due to the “cross-over” to autologous SCT 
of patients failing conventional therapy.5,8,32 The 
treatment-related mortality (TRM) in 3 randomized 
studies was similar between HDC and conventional 
chemotherapy, likely due to the relatively high toxicity 
of chemotherapy used in the conventional arm.33 
Although initial studies reported an average TRM of 
10% (range, 3 - 17%), randomized studies (Table 1) 
reported a lower TRM (3 - 4%), likely due to better 
supportive care, the use of peripheral blood stem cells 
(PBSC) instead of bone marrow (BM), and earlier 
referral of patients to autografting. Long-term toxicity, 
including heart, lung and endocrine toxicities, as well 
as infections, infertility, and secondary malignancies 
should also be considered during counseling. A 
consensus study from several cooperative groups 
suggested that as early as 6 months after the start of 
HDC, patients should receive a specific follow-up for 
the early detection of complications.34 An analysis 
involving more than 800 patients autografted for 
hematological malignancies who survived more than 2 
years after transplant showed that their risk of late 
death was 13-fold higher than in the general 
population, particularly in the first 2-5 years after 
HDC. For cHL patients, the standardized mortality 
ratio (SMR) was 28, meaning that these patients had a 
28-fold increased risk of dying compared with the 
general population. Furthermore, the most frequent 
specific causes of death were secondary cancers and 
lung disease (SMR 30 and 29, respectively).34 
 
Prognostic Factors and Risk-Adapted Strategies. 
Factors shown to influence the outcome of 
relapsed/refractory patients have led to the generation 
of prognostic scores for the risk stratification of 
patients undergoing HDC and autologous SCT 
(summarized in Table 2). The most popular scoring 
system is the German Score (GS), which incorporates 3 
variables, including anemia, stage III-IV, and time to 
relapse less than 12 months.35,36 The GS was validated 
by the randomized HDR2 study, which showed a 3-
year PFS of 81%, 70%, 50%, and 14% in patients with 
adverse factors ranging from 1 to 4, respectively.32 
Majhail et al.10 analyzed 141 patients and identified the 
3 following variables as being predictive of outcome: 
chemoresistance, B symptoms at relapse, and 
persistence of disease at transplant. According to this 
score, the figures for 5-year PFS were 67%, 37% and 
9% for patients with 0-1, 2, and 3 factors, respectively. 
Similarly, the 5-year OS was significantly different 
among the 3 groups, with respective values of 71%, 
49%, and 13%.10  
Prognostic scores have also been used prospectively 
to evaluate the clinical impact of risk-adapted 
therapeutic programs. Moskowitz et al.37 used 
standard-dose ICE for low-risk patients, intensified-
ICE for intermediate-risk patients, and ICE plus 
autologous SCT for high-risk patients and showed that 
risk-adapted augmentation of salvage treatment 
improved event-free survival in higher risk patients.
 
Table 1.  Randomized studies of autologous SCT in cHL. 




Linch 40 BEAM vs. Mini-BEAM 78% vs. 60% ** 53% vs. 10% 10% vs. 0 BM 5 
Schmitz 144 BEAM vs. Dexa-BEAM 71% vs. 65% ** 55% vs. 34% 6 vs. 6 pts PBSC 8 
Josting * 241 BEAM vs. HDS-CT 87% vs. 80% ** 67% vs. 72% ** 2% PBSC 32 
Abbreviations: BEAM, carmustine, etoposide, cytarabine, melphalan; HDS, high-dose sequential chemotherapy; OS, overall survival; PFS, 
progression-free survival; TRM, treatment related mortality; BM, bone marrow; PBSC, peripheral blood stem cells. 
* The standard arm consisted of BEAM, and the experimental arm consisted of HDS-CT plus BEAM. 
** Not significant. 
 Mediterr J Hematol Infect Dis www.mjhid.org 2015; 7: Open Journal System 
Table 2.  Prognostic scores for relapsed/refractory cHL. 
Author n Variables OS PFS Refs. 
Lohri 71 
B symptoms 
Relapse <12 mos. 
Stage IV 
NA 
0 = 82% 




Relapse <12 mos. 
Extranodal disease 
NA 
0 = 97% 
1 = 87% 
2 = 47% 
3 = 1% 
76 
Brice 280 
Relapse in previous RT sites 
Stage III-IV 
Relapse <12 mos. 
NA  39 
Horning 119 
B symptoms 
Stage IV (lung/bone marrow) 
Residual disease at transplant 
NA 
0 = 85% 
1 = 57% 
2 = 41% 
≥3 = <20% 
77 
Josting 422 
Hb levels (< 10, < 12) 
Stage III-IV 
Relapse <12 mos. 
NA 
0 = 100% 
1 = 70% 
2 = 55% 




Extranodal disease  
Relapse <12 mos./refractory 
0-1 = 90% 
2 = 57% 
3 = 25% 
0-1 = 83% 
2 = 27% 








Residual disease at transplant 
0-1 = 71% 
2 = 49% 
3 = 13% 
0-1 = 67% 
2 = 37% 
3 = 9% 
10 
Abbreviations: OS, overall survival; PFS, progression-free survival; mos., months; NA, not available. 
 
Morschhauser et al.38 subsequently tested the 
prognostic score proposed by Brice et al.39 This score 
included advanced stage disease, duration of first 
response shorter than 12 months, disease relapse in 
irradiated fields, and refractoriness to first-line 
chemotherapy. Intermediate-risk patients received 
conventional salvage chemotherapy followed by 
BEAM, whereas high-risk patients (chemorefractory or 
bearing more than 2 risk factors) were treated with 
intensified salvage chemotherapy and double 
autologous SCT (CBV-Mx or BEAM and TAM or 
BAM).38 The 5-year freedom from second failure 
(FF2F) and OS rates were 46% and 57% in the high-
risk group and 73% and 85% in the intermediate-risk 
group. The overall efficacy of salvage chemotherapy 
was not optimal, as the objective response rate (ORR) 
was 63%, and this value was even lower among high-
risk patients (ORR 54%, CR/Cru 23%).38 Although the 
results obtained with tandem autologous SCT in the 
poor prognosis group were better than those reported in 
other trials (Table 3), they are still unsatisfactory, 
further supporting the requirement for new therapeutic 
strategies. A study from the Royal Marsden involving 
patients with relapsed or refractory disease and a 10-
year follow-up reported PFS and OS figures of 49% 
and 37%, respectively. Chemosensitive disease and a 
Hasenclever index <3 at SCT were the two prognostic 
factors for OS and PFS.40  
 
Primary Refractory cHL. Chemorefractoriness to first-
line therapy represents the strongest factor predicting a 
poor outcome after autologous SCT. These patients 
were not included in randomized trials, and 
autografting resulted in 30% to 40% durable PFS, once 
again supporting the general concept of poorer 
outcome in chemorefractory patients compared with 
chemosensitive patients (Table 3). In a study from the 
German group, 206 primary progressive patients were 
analyzed and 153 received salvage chemotherapy, of 
which only 70 (34%) were autografted, whereas 47 
received salvage radiotherapy.36 The 5-year FF2F and 
OS for all patients were 17% and 26%, respectively; 
the same figures for patients treated with HDC were 
31% and 43%, respectively. The identification of three 
prognostic factors, including an age >50 years, failure 
to obtain temporary remission after first-line 
chemotherapy, and poor performance status, enabled 
the design of a prognostic score. Combining these 
factors, the 5-year OS ranged from 56% (absence of 
adverse factors) to 0% (presence of all 3 factors).36 
Uncontrolled disease prior to autologous SCT, either 
stable or progressive, was included for a small group of 
very high-risk patients and generated an OS ranging 
from 11% to 37% (Table 4). Furthermore, in most of 
the studies dealing with mixed cohorts of patients with 
relapsed or refractory disease, the absence of 
chemosensitivity before autografting negatively 
influenced the outcome. Therefore, biomarkers 
enabling the early identification of chemorefractory 
patients (such as CD68 expression on macrophages,41 
PD-1/PD-L1 expression on Hodgkin Reed-Sternberg 
cells or microenvironment cells,42 etc.), novel agents 
specifically targeting tumor cells along with the tumor 
microenvironment at the genetic or epigenetic level, as 
well as innovative therapeutic strategies are urgently 
needed for chemorefractory patients. 
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André 86 CTS 62% Several - 
35%@5y 
CR = 60% 
PD = 20% 
25%@5y 8% BM 78 
Sweethenam 175 NA CBV, BEAM - 36%@5y 32%@5y 14% BM 79 
Josting*  206 CTS 43% CBV, BEAM + 
43%@5y 
0 = 55% 













Moskowitz 75 CTS 64% 
TLI, IFRT, CTX, 
VP16 
- 48%@10y 49%@10y 10% PBSC 9 
Morabito 27 NA Several - 81%@4y NA NA NA 82 
Akhtar 66 CTS 84% BEAM - 64% 36% 3% PBSC 83 
Morshhauser 77 CTS 53% 
BEAM like 
+TAM 
+ 53%@5y 41%@5y** 4% PBSC 38 
Abbreviations: CTS, chemosensitive disease; NA, not available; CBV, cyclophosphamide, etoposide, carmustine; BEAM, carmustine, 
etoposide, cytarabine, melphalan; TLI, total lymphoid irradiation; IFRT, involved-field radiation therapy; CTX, cyclophosphamide; VP16, 
etoposide; TAM, fractionated total body irradiation, cytarabine, melphalan; OS, overall survival; PFS, progression free survival; TRM, 
treatment related mortality; BM, bone marrow; PBSC, peripheral blood stem cells.  
*The results were given based on the presence of the 3 following prognostic factors: low Karnofsky performance score at progression, age 
>50 years, and failure to achieve a temporary remission after first-line therapy. 
** Reported as freedom from second failure (FF2F). 
 
Table 4.  Clinical outcome of patients with chemorefractory disease after receiving autologous SCT. 
Abbreviations: NA, not available; OS: overall survival; PFS: progression-free survival. 
 
Conditioning Regimens. The potential benefit of a 
conditioning regimen has not been adequately explored 
in the autologous setting. Two randomized studies 
applied the BEAM conditioning regimen,5,8 which was 
introduced several years ago but not previously tested 
in randomized trials. Nevertheless, this regimen is 
considered the gold standard for autologous 
transplantation. When salvage chemotherapy followed 
by BEAM was compared with a more intensive high-
dose sequential therapy (HDS-CT), the outcomes were 
not different, although the toxicities were higher in the 
HDS-CT arm.32 Evidence emerging from several recent 
studies also supports the concept that alternative 
conditioning regimens are not more effective and/or 
less toxic than BEAM. In the event that a randomized 
study comparing BEAM with newer regimens is not 
performed, the BEAM regimen may be considered the 
gold standard. However, due to drug constraints on 
carmustine, this drug is often replaced by a variety of 
agents, including fotemustine,43 bendamustine,44 and 
thiotepa.45  
 
Role of PET Imaging. The extensive use of 18F-
fluorodeoxyglucose positron emission tomography 
(FDG-PET) over the past 10 years has resulted in 
significant changes in the outcomes of 
relapsed/refractory patients, as some patients classified 
as PR or SD, or rarely PD after salvage chemotherapy, 
may in fact be in metabolic CR. The bottom line is that 
FDG-PET segregates patients into 2 groups: positive 
and negative. The available data show that a positive 
FDG-PET before autografting identifies patients with 
Author OS PFS Refs. 
Chopra NA 33% 84 
Rapoport NA 15% 85 
Yahalom NA 7% 86 
Crump NA 26% 87 
André 19% NA 78 
Argiris NA 22% 88 
Josting 3 alive NA 36 
Lazarus 37% 19% 89 
Sureda NA 17% 90 
Fermè NA NA 91 
Tarella 36% 33% 92 
Czyz 17% NA 81 
Majhail 13%@5y NA 10 
Gopal 31%@5y NA 11 
Morshhauser 21% 31% 38 
Sirohi 11% 7% 40 
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poorer outcome than those with negative FDG-PET.37 
However, the outcome of the FDG-PET positive group 
(OS 40-58%, PFS 23-40%) is often unsatisfactory, and 
newer approaches should be tested for their ability to 
obtain FDG-PET negativity. However, the early 
application of allogeneic SCT in FDG-PET positive 
patients was reported by the English group, with 
encouraging results (3-year PFS 68% and OS 88%).46 
Interestingly, the use of FDG-PET overcame the 
impact of prognostic factors (B symptoms, early 
relapse/refractoriness), with the exception of extra-
nodal localization.47 Castagna et al. also showed that in 
the context of salvage therapy, interim FDG-PET could 
predict PFS.48 Prospective studies are currently 
ongoing, in which the treatment strategy is changed 
based on the FDG-PET results, after first-line or 
second-line chemotherapy. Devillier et al.49 recently 
published a retrospective study on 111 patients, 
confirming the predictive value of the response by 
FDG-PET at autografting (5-year PFS and OS, 79% vs. 
23% and 90% vs. 55% in FDG-PET negative and 
positive patients, respectively). Furthermore, in FDG-
PET positive patients, the outcome was better if they 
received a double transplant.49 Therefore, defining the 
therapeutic response with FDG-PET represents the 
most relevant improvement in the treatment of 
advanced cHL, challenging most of the data generated 
in recent years.47  
The prognosis of patients who fail autologous SCT 
is poor.15 A joint EBMT and GITMO retrospective 
analysis on 462 patients who relapsed or progressed 
after autologous SCT showed a median time from SCT 
to relapse of 7 months (range, 1 - 78) and a 5-year OS 
for the entire cohort of 32%.16 In multivariate analysis, 
early relapse, stage IV, bulky disease, poor 
performance status, and age ≥50 years were 
significantly associated with survival, and 3 groups (0, 
1, ≥2 factors) showed different OS rates (62%, 37%, 
and 12%, respectively).16 Thus, patients with refractory 
disease and patients failing autologous SCT represent 
an unmet medical need requiring innovative 
treatment.50  
 
Allogeneic SCT.  
Clinical results from retrospective trials of allogeneic 
SCT reported in the early nineties were disappointing, 
likely due to the inclusion of heavily pretreated 
patients, who had received extended radiotherapy and 
were allografted in the presence of active disease after 
myeloablative conditioning with bone marrow stem 
cells (reviewed in Sureda et al.51). Allogeneic SCT has 
been associated with a high TRM due to the high 
incidence of graft versus host disease (GVHD) and 
fatal infections post-transplantation. The poor outcome 
of cHL patients after allogeneic SCT may reflect, in 
part, the advanced status of the disease at 
transplantation and the poor performance status of the 
patient population that was allografted. Furthermore, 
the high TRM present in the conventional allogeneic 
SCT setting has never allowed proper evaluation of a 
possible graft-versus-Hodgkin's effect. In the late 
nineties, this scenario changed substantially with the 
introduction of reduced intensity conditioning (RIC) 
and non-myeloablative conditioning (NMAC) 
regimens (Table 5). As a matter of fact, a clinically 
significant reduction of TRM below 30% was reported 
by several investigators and resulted in a renewed 
interest in allogeneic SCT. On average, PFS ranged 
from 20% to 42% and OS from 25% to 57%. Such a 
wide variability is mainly due to the heterogeneity of 
patients included in these retrospective trials. Despite 
representing an increasingly used procedure, allogeneic 
SCT remains a matter of discussion, and several 
controversial issues are currently under investigation.  
One general question that needs to be addressed is 
how allogeneic SCT compares with other therapies. In 
the absence of randomized trials, figures extrapolated 
from retrospective studies have to be considered with
 







PFS OS TRM Refs. 
Robinson 52 NA CTS 67% 45%@2y 42%@2y 56%@2y 17%@2y 93 
Peggs 49 31/18 CTS 67% 33%@4y 39%@4y 55%@4y 15%@2y 72 
Alvarez  40 37/2 CTS 50% NA 32%@2y 48%@2y 25%@1y 94 
Todisco  14 11/3 CTS 57% NA 25%@2y 57%@2y 0 95 
Corradini 32 32/0 CTS 62% 81%@3y NA 32%@3y 3%@3y 30 
Anderlini 58 25/33 CTS 52% 61%@2y 20%@2y 48%@2y 15%@2y 96 
Devetten 143 143 CTS 44% 47%@2y 20%@2y 37%@2y 33%@2y 97 
Robinson 285 172/94 CTS 59% 53%@3y 29%@4y 25%@4y 19%@1y 28 
Sureda 92 55/23 CTS 67% 59%@4y 24%@4y 43%@4y 15%@1y 71 
Abbreviations: MRD, matched-related donor; MUD, matched-unrelated donor; OS, overall survival; PFS, progression-free survival; TRM, 
treatment related mortality; NA, not available; CTS, chemosensitive disease. 
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caution. An EBMT/GITMO study retrospectively 
analyzed the risk factors predicting the outcome of 
cHL patients relapsing after autologous SCT.16 A total 
of 462 patients were treated with either conventional 
chemotherapy eventually supplemented by 
radiotherapy (64%), a second autologous SCT (9%) or 
allogeneic SCT (29%). At a median follow-up of 49 
months, 2-year and 5-year OS rates were 55% and 
32%. In multivariate analysis, allogeneic SCT was 
associated with a trend towards improved survival (P = 
0.08).16 In fact, the OS at 5 years was 48% for patients 
receiving allogeneic SCT (RIC) and 32% for those 
treated with conventional chemotherapy/radiotherapy, 
with a median survival time of 45 and 19 months, 
respectively. Independent risk factors predicting a poor 
OS were early relapse within the first 6 months after 
HDC, stage IV disease, bulky disease, presence of B 
symptoms, a Karnofsky performance status under 80% 
and age of 50 years or older. Patients presenting with 
none of these risk factors had a 5-year OS rate of 62%, 
whereas among patients presenting with one risk 
factor, the 5-year OS rate was 37%. In contrast, 
patients with two or more risk factors had a poor 
clinical outcome, with a 5-year OS rate of only 12%.  
 
Novel Agents and Allogeneic SCT. Several 
retrospective studies have suggested that allogeneic 
SCT should be considered a therapeutic option in 
patients relapsing or progressing after 
autografting.25,46,52 The current availability of active, 
although non-curative drugs, such as BV,20,21 
nivolumab,22 bendamustine,23,24,53 histone deacetylase 
inhibitors,54,55 mTOR inhibitors,56 kinase inhibitors,57,58 
and immunomodulatory drugs,59 has allowed 
substantially high rates of objective responses in 
patients who previously failed autologous SCT, thus 
resulting in significant improvements of the quality and 
quantity of clinical responses achieved by patients who 
became eligible for allogeneic SCT after having failed 
autografting. Recently, Chen et al.60 compared a small 
cohort of patients (n = 21) receiving BV before 
allogeneic SCT with historical controls (n= 23). The 
BV cohort showed better 2-year PFS (59% vs. 26%) 
and OS (71% vs. 56%), with a lower relapse rate (24% 
vs. 57%) and 1-year NRM of 9.5% vs. 17%. 
Interestingly, these treatments shared a good toxicity 
profile, thus allowing patients to achieve a good 
performance status at the time of allografting.  
Allogeneic SCT could also be a viable option for 
patients who are refractory to salvage chemotherapy, 
especially because better results are obtained when this 
treatment is applied earlier.61 Indeed, the survival of 
these patients is poor, and most of them die from 
disease progression.62 The availability of novel agents 
resulting in objective responses may eventually result 
in increased eligibility for allogeneic SCT (Figures 
1,2).  
 
Figure 1 – Treatment algorithm for relapsed/refractory cHL 
 
 
Abbreviations: TX, therapy; RT, radiotherapy; CR, complete remission; PR, partial remission. 
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Figure 2 – Treatment algorithm for cHL relapsing or progressing following Auto-SCT 
 
Abbreviations: CR, complete remission; PR, partial remission; RT, radiotherapy. 
 
Recently, the UK group reported interesting results 
in patients who were FDG-PET positive after salvage 
chemotherapy and treated with allogeneic SCT. For 
most of these patients, the conditioning regimen 
consisted of BEAM plus Campath, and the results were 
encouraging because the 3-year NRM, PFS, and OS 
rates were 24%, 68%, and 80%, respectively.46 In 
general, for patients refractory to salvage CT, 
allogeneic SCT should be considered, provided that 
good disease control is achieved prior to 
transplantation.63 
 
Conditioning Regimens. The type of conditioning 
regimen to be used prior to allogeneic SCT represents 
another matter of discussion. There is a consensus that 
RIC should be preferred to MAC regimens. Indeed, in 
a retrospective registry-based study, Sureda et al. 
reported that patients receiving MAC had lower OS 
rates than those treated with RIC.26 However, it should 
be noted that after MAC, even though NRM was 
higher, the relapse rate was lower, meaning that new 
and less toxic myeloablative regimens should be 
prospectively evaluated.  
 
Prognostic Factors. Several prognostic factors 
associated with different outcomes after allogeneic 
SCT have been reported. In a large retrospective study 
from EBMT, Robinson et al.28 reported that prognostic 
factors may help to define different patient populations 
with significantly different outcomes (Table 6); the 
most important and recurrent factor was the disease 
status before allogeneic SCT, as patients not achieving 
CR at the time of transplantation experienced shorter 
survival, increased toxicity and relapse. Furthermore,
 
Table 6.  Prognostic factors at allogeneic SCT (adapted from Robinson et al.28).  
 3-y OS 3-y PFS 3-y DPR 3-y NRM 
Risk Factors at Transplant 
 
Refractory 











0 56% 42% 47% 12% 
≥1 25% 8% - - 
≥2 - - 70% 46% 
Abbreviations: OS, overall survival; PFS, progression-free survival; DPR, disease-progression rate; NRM, non-relapse mortality; PS, 
performance status; CT, chemotherapy; F/M, male recipients of female donors.  
* Karnofsky <80% or ECOG 2-3. 
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in patients allografted after autologous SCT, the 
interval between relapse and autografting (cut-off 6 
months) was a protective prognostic factor. In contrast 
with other studies, which demonstrated a reduction of 
relapse in patients experiencing chronic GVHD 
(cGVHD),26,63 the EBMT study failed to show a link 
between the development of cGVHD and survival.28   
 
Donor Source. The vast majority of allografting in cHL 
stemmed from studies using either an HLA-identical 
sibling or a matched unrelated donor (MUD). With a 
median NRM of 10% (range, 3-25%), the use of HLA-
identical siblings is considered a standard option due to 
its good toxicity profile. Because only 25-30% of 
patients have an HLA-identical sibling, searching for a 
MUD is mandatory, despite the consistent increase in 
median NRM to 28% (range 16-34). In recent years, 
great interest has been focused on haploidentical family 
donors (HLA-haplo). Encouraging results have been 
obtained using the Baltimore approach, combining 
NMAC regimens, T cell-replete BM and post-
transplant cyclophosphamide (Cy).64 This scheme is 
well tolerated and has shown a remarkably low NRM, 
with good OS in a variety of hematological 
malignancies.65,66 Two retrospective studies have 
reported the activity of transplantation from 
haploidentical family donors. Burroughs et al. 
compared the results obtained in patients receiving 
transplantation from a matched related donor (MRD), 
MUD, or haploidentical family donor.67 The PFS, 
NRM, and relapse rates were significantly lower after 
haploidentical transplantation than transplantation 
using other stem cell sources. Furthermore, the 
incidence of acute and chronic GVHD was equally 
lower in the haploidentical group.67 More recently, 
Raiola et al. reported 26 cHL patients grafted from 
haploidentical family donors with rates of PFS, OS, 
relapse, and NRM of 63%, 77%, 31%, and 4%, 
respectively.65 Additionally, this study confirmed the 
low incidence of both acute GVHD (grade 2-4, 24%) 
and cGVHD (9%).65 Altough preliminary and based on 
a limited number of patients, the extraordinary efficacy 
of this strategy of haploidentical transplant suggests a 
peculiar role of the conditioning regimen in eliciting an 
HL-specific immune activity.    
 
Management of Disease Relapse after Allogeneic SCT. 
Notwithstanding the reduction of NRM and GVHD, 
disease relapse following allogeneic SCT ranges from 
31% to 81% in different series and still represents a 
major issue that needs to be addressed. In particular, 
the survival of relapsing patients is dismal. Ram et al. 
analyzed the outcome of 26 cHL patients and reported 
that the 3-year OS was 47%, with a median time from 
allografting to relapse of 6 months (range, 0.5-29 
months). Different therapies were administered, 
including withdrawal of immunosuppressive therapy, 
standard chemotherapy eventually combined with 
radiotherapy, donor lymphocyte infusion (DLI), or a 
second allogeneic transplantation. This translated to an 
ORR of 78%, which was, however, associated with a 
high risk of further progression.31 A second 
retrospective study in 28 cHL patients reported a 
survival rate of 49% and identified late relapse (cut off 
100 days), achievement of CR/PR, and localized nodal 
or extra-nodal relapse as significant predictive 
factors.68 We reported a series of 97 HL patients 
receiving allogeneic SCT at either Humanitas Cancer 
Center (Rozzano, Italy) or Institut Paoli Calmettes 
(Marseille, France). Thirty-three (34%) patients 
relapsed after a median time from allografting of 4.5 
months (range, 0.3-17 months). In this series, the 
median follow-up time was 46 months (range, 1-160 
months), and the 2-y PFS and OS were 17% and 33%. 
We also confirmed that patients with late relapse 
showed a better prognosis (Castagna L. et al., 
manuscript in preparation). 
Survival data from the EBMT/GITMO study, as 
well as other series, strongly suggest that allogeneic 
SCT is feasible and appears to be active in at least one 
third of multi-relapsed patients. However, this 
treatment modality cannot be considered a standard 
procedure and should be offered to carefully selected 
chemosensitive patients included in clinical studies. 
However, the availability of new active drugs to be 
used alone or in combination, and eventually 
associated with DLI, could substantially change this 
scenario.  
The implementation of novel agents, such as BV, 
nivolumab, and bendamustine, for the treatment of 
multi-relapsed cHL patients has improved the outcome 
of these patients and will significantly impact the 
history of multi-relapsed cHL in the near future when 
the results of combination studies become available. 
Two studies have reported similar efficacy data of BV 
used as single agent in patients with recurrent disease 
after allogeneic SCT.69,70 The largest study of BV after 
allografting failure involved 24 patients who received a 
median of 8 cycles (range, 1-16) of BV at a median of 
42 months (range, 6-116) after allografting. After a 
median follow-up time of 34 weeks, these patients 
showed ORR and CR rates of 50% and 38%, 
respectively, with a median PFS of 7.8 months, 
whereas the median OS was not reached.69 The toxicity 
profile was good, without any impact on GVHD or 
CMV reactivation.69 The largest cohort study of 
bendamustine in cHL patients with recurrent disease 
after allogeneic SCT was recently reported.23 In a 
multicenter retrospective study, 45 and 22 patients 
received bendamustine for disease recurrence after 
autologous and allogeneic SCT, respectively; most of 
these patients received 90 mg/m2 x 2 days (73%). The 
CR+PR rates for patients treated with bendamustine 
due to recurrence after autologous or allogeneic SCT 
were 56% and 59%, respectively, whereas the same 
figures for patients achieving SD+PD were 44% and 
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41%, respectively. After a median follow-up time of 13 
months, the PFS was 49%, and OS was 70% at 1 year. 
The median PFS was 10 months, whereas the median 
OS was not established. Toxicities were manageable, 
with grade 3-4 hematological toxicity being evident in 
less than 20% of patients. The most common extra-
hematological toxicities were fever and febrile 
neutropenia.23  
DLI has been used frequently, resulting in an 
average ORR ranging from 40% to 80%. However, in 
most cases, the duration of the response was short and 
almost all patients relapsed.71 Of special interest are the 
data from the English group, showing that disease 
relapse was extremely rare in patients receiving DLI 
when in CR after allogeneic SCT and with mixed 
chimerism. Overall, the 4-year OS was 59%. This 
result may confirm the immunological effect of donor 
lymphocytes in the situation of minimal residual 
disease.72 DLI has also been combined with other 
drugs. In a proof-of-principle study, Teurich et al. 
treated 4 patients with the combination of BV plus DLI 
and demonstrated an immunological effect on HL cell 
lines mediated by heterogeneous CD161-positive 
lymphocytes.73 In addition, all patients showed a 
metabolic response. In a multicenter retrospective 
study, Sala et al. assessed 18 patients receiving 
bendamustine, 9 of them in association with DLI, and 
the 1-year OS and PFS rates were 59% and 30%, 
respectively.74 
 
Conclusions. Autologous SCT have become the 
standard of care for refractory/relapsed cHL, leading to 
durable responses in approximately 50% of relapsed 
patients and a minority of refractory patients (Figure 
1). Furthermore, the current availability of active, yet 
non-curative, drugs has significantly improved the 
management of autografting failures, allowing for 
substantially increased rates of objective responses. In 
particular, these treatments have resulted in significant 
quantitative and qualitative improvements in the 
clinical responses of patients who have subsequently 
become eligible for allogeneic SCT after having failed 
autografting (Figure 2). Patients achieving PET-
negativity after a second salvage regimen may do well 
with autologous SCT even though they were PET-
positive after the first salvage regimen.47 However, 
retrospective data in the setting of haploidentical SCT 
report a low TRM and suggest the existence of 
clinically relevant, graft-induced immune effects, thus 
suggesting that allogeneic SCT can be offered to 
chemorefractory cHL patients, as well as to those 
patients who fail autologous SCT and achieve CR or 
PR using novel agents.61 Despite the reduction of NRM 
and GVHD, disease relapse still represents the major 
issue in the setting of allogeneic SCT failure. Novel 
biomarkers for the early identification of relapsing and 
refractory patients, as well as novel agents specifically 
targeting genetic or epigenetic changes in both tumor 
cells and the tumor microenvironment, are needed for 
refractory patients. Together, the integration of novel 
prognostic biomarkers, novel agents and allogeneic 
SCT will significantly impact the history of multi-
relapsed and refractory patients, overcoming the issues 
of chemorefractoriness as well as disease relapse. 
Finally, the long-term toxicities of such treatments 
should be carefully evaluated, and specific follow-up, 
which ideally would be given in specialized clinics, 
should become part of global care.  
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